Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive fibromatosis (desmoid tumor)~* Relapse or disease progression despite surgery, chemotherapy, radiotherapy, or any other treatment~* Tumors must meet the following criteria:~  * Ineligible for complete surgical resection by carcinological exeresis OR surgery would cause severe mutilation~ * Cannot be treated with curative radiotherapy~* Measurable disease by RECIST criteria~* No prior malignancy~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after completion of study treatment~* Absolute neutrophil count \> 1,000/mm\^3~* Platelet count \> 100,000/mm\^3~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* SGOT and SGPT \< 2.5 times ULN~* Creatinine ≤ 2.5 times normal~* No severe liver failure~* No chronic somatic or psychiatric illness that would preclude study compliance~* No known hypersensitivity to imatinib mesylate or one of its components~* No geographical, social, or psychological reason that would inhibit follow-up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent immunomodulators\*~* No concurrent hormonal treatments\* if used for fibromatosis~* No concurrent cytotoxic drugs\*~* No concurrent nonsteroidal anti-inflammatory drug\* if used for fibromatosis~  * Allowed if used as an analgesic 3 months prior to disease progression~* No concurrent participation in another therapeutic investigational trial NOTE: \*If disease progression has occurred during this treatment, then the treatment must have ended ≥ 1 month prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): 400 to 800 mg/day for a maximal 12 months study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).